In this study, we showed that bacteria can colonize electrophysiological devices without signs of infection. Because only a few of the patients with bacteria detected at the time of device removal developed an infection during follow-up, antibiotic treatment is probably not indicated in these patients. However, the role of colonizing bacteria in the development in infection must be further elucidated, and perioperative antibiotic prophylaxis with additional coverage of coagulase-negative staphylococci and Propionibacterium acnes should be evaluated. Additionally, we showed that bacteria on electrophysiological devices can be better detected with sonication than with conventional swab culture, suggesting that sonication of removed infected devices might be more sensitive in isolating bacteria, especially when patients are already receiving antibiotic treatment. See p 1691.
Effect of Long-Term Right Ventricular Pacing in Young Adults With Structurally Normal Heart
This study elucidates the long term effect of right ventricular (RV) pacing on clinical outcomes in patients who underwent pacemaker implantation for symptomatic isolated congenital complete atrioventricular block (ICAVB). Over a mean follow-up of 20 years (longest 39 years) the observed survival free of new heart failure (HF) after pacemaker implant in the overall ICAVB group was significantly worse than that of the age-and sex-specific Olmsted County, Minnesota population rates. This difference was, however, attributable to the development of HF and ventricular dysfunction in those who had tested positive for antinuclear antibody (ANA) during adulthood with no difference between the antibody negative ICAVB patients and the Olmsted County population. The presence of a positive ANA was a strong predictor for the development of HF and death. These results suggest that in young patients without structural heart disease, pacing from the RV position does not appear to have a detrimental effect on heart size or performance. The risk of HF after pacemaker implant is not solely the result of abnormal ventricular activation, but instead an interaction between pacing and abnormal myocardial substrate. In ICAVB patients, positive antibody status may predispose to cardiomyopathy and worse clinical outcomes. ANA testing should supplement the assessment of ventricular size and function by echocardiography to identify high-risk patients who might progress to HF. See p 1698.
Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A
Homozygous or double heterozygous factor V Leiden and/or prothrombin G20210A is a rare inherited thrombophilic trait. Although individuals who have these mutations are at an Ϸ20-fold increased risk of first venous thrombosis, it is uncertain whether the risk of recurrence in these individuals is also increased. The clinical implications for such individuals, such as receiving anticoagulant treatment for an indefinite time after first venous thrombosis, depend on the risk of recurrence. In this case-control study, performed in a large cohort of thrombophilic families, we assessed the risk of recurrence of venous thrombosis in individuals with homozygosity or double heterozygosity for factor V Leiden and prothrombin G20210A. The cohort consisted of 788 individuals with prior venous thrombosis, of whom 325 had recurrent events. A total of 494 mutations were identified. Compared with noncarriers, carriers of the mutations factor V Leiden (nϭ283), prothrombin G20210A (nϭ82), double heterozygous (nϭ49) or homozygous factor V Leiden, or homozygous prothrombin G20210A (nϭ27) did not display an increased risk of recurrent events. Testing for these genetic mutations in patients with first venous thrombosis seems therefore to be of limited use. See p 1706.
Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
M118 is a novel low-molecular-weight heparin that has been rationally designed to capture the desired attributes of both unfractionated heparin and low-molecular-weight heparin: Potent activity against both factor Xa and IIa, predictable pharmacokinetics after both intravenous and subcutaneous administration, ability to be monitored by use of point-of-care coagulation assays, and reversibility with protamine sulfate. We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention. The results of the EMINENCE trial demonstrate that M118 is well tolerated and feasible to use as anticoagulant therapy during percutaneous coronary intervention. It exhibits a dose-dependent increase in the activated clotting time and is noninferior to unfractionated heparin with respect to a broad composite of end points that reflect complications related to percutaneous coronary intervention. In addition to clinical outcomes, angiographic outcomes were excellent and comparable between unfractionated heparin and M118. Although a range of doses of intravenous M118 were comparable to unfractionated heparin at preventing a broad composite of percutaneous coronary intervention-related complications, we conclude that a dose range of 75 to 100 IU/kg appears most promising and should be tested further in a phase 3 trial. See p 1713.
Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
Hypertriglyceridemia is a common form of dyslipidemia that is frequently linked to premature coronary artery disease. Hypertriglyceridemic patients often exhibit a small, dense low-density lipoprotein (LDL) phenotype. Our previous investigations demonstrate that apolipoprotein (apo) C-III and E, surface protein components of very low-density lipoprotein (VLDL) and LDL, play a dominant role in regulating the metabolism of these lipoproteins. In this work, we studied VLDL and LDL metabolism by the kinetics of its principal protein component, apoB, in 9 patients with moderate hypertriglyceridemia and 12 normotriglyceridemic control subjects using stable isotope labeling. Our results support a central role for apoC-III in VLDL and LDL metabolic defects leading to hypertriglyceridemia. Triglyceride-rich lipoprotein metabolism shifts from an apoEdominated system in normolipidemic participants characterized by rapid clearance from the circulation of VLDL to an apoC-IIIdominated system in hypertriglyceridemic patients characterized by
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Original Research Put Into Perspective for the Practicing Clinician Volume 121 Ⅲ Number 15 Ⅲ April 20, 2010 reduced clearance of triglyceride-rich lipoproteins that are channeled to formation of dense LDL in plasma. In addition, apoC-III contributes to the formation of the dense LDL phenotype through a quartet of kinetic perturbations. These results indicate that the action of apoC-III to retard clearance of triglyceride-rich lipoproteins is a central metabolic feature underlying major changes in VLDL and LDL metabolism in hypertriglyceridemia. These adverse changes in apoB lipoprotein metabolism caused by apoC-III, in addition to the newly established proatherogenic effects of apoC-III itself, directly link moderate hypertriglyceridemia to increased risk for coronary heart disease. Therefore, modulating apoC-III may not only improve lipid profiles but also prevent the development of atherosclerotic plaques and their acute thrombotic complications. See p 1722.
Human Adult Vena Saphena Contains Perivascular Progenitor Cells Endowed With Clonogenic and Proangiogenic Potential
This study is the first to demonstrate that saphenous leftovers, designed to be discarded after bypass surgery, are indeed an invaluable source of perivascular progenitor cells. These cells can be expanded and stored for subsequent autologous transplantation with the aim of promoting therapeutic angiogenesis. Other potential therapeutic exploitations include use in diseases characterized by impairment of perivascular support cells, such as diabetic microangiopathy, and the application of saphenous vein-derived progenitor cells for the promotion of vein graft adaptation, by seeding them on periadventitial stents. These potential applications will require proof of concept and further preclinical validation. See p 1735.
Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice
Atherosclerotic lesion progression depends on chronic inflammation within the artery wall, and T cells are involved in the immune response that accompanies atherogenesis. Interleukin (IL)-17A is a recently discovered cytokine that plays a protective role in host defenses against extracellular pathogens and a pathogenic role in several autoimmune diseases, including multiple sclerosis, inflammatory bowel disease, and arthritis. In the present study, we showed that plasma levels of IL-17A and aortic IL-17A-producing ␥␦ ϩ and CD4 ϩ (Th17) T cells were significantly elevated in the atherosclerosis-prone conditions found in apolipoprotein E-deficient (Apoe Ϫ/Ϫ ) mice. We confirmed a proatherogenic role of IL-17A using adenovirus-delivered soluble IL-17 receptor against IL-17A, which caused a significant decrease in plasma levels of IL-6 and granulocyte colony-stimulating factor, diminished aortic macrophage content and CXCL1 expression, and led to a reduction in plaque burden in treated Apoe Ϫ/Ϫ mice. Conversely, the treatment of isolated Apoe Ϫ/Ϫ aortas with recombinant IL-17A increased CXCL1 expression and monocyte adhesion to vessel wall. Our findings highlight a proatherogenic role for IL-17A in coronary atherosclerosis and suggest that future therapies targeting IL-17A could potentially reduce vascular wall infiltrates and lesion size and attenuate atherosclerosis and other forms of vascular disease. See p 1746.
